ANZCTR search results

The aim of this research study is to compare the efficacy and cost effectiveness of three online interventions targeting healthy eating in young Australian adults aged 18-24 years. Each group will vary in level of technology delivered personalised feedback they will receive on their dietary patterns and other support strategies offered for them to improve their diet quality and eating habits.

This is a double-blind, randomised, comparator-controlled, four (4) arm, prospective investigation. The primary objective of this clinical investigation is to identify the optimal configuration of TrimphDent required to produce a clinical outcome similar to or better than that of autologous bone graft. The secondary objective of the clinical investigation is to evaluate the safety and usability of TrimphDent.

Excess consumption of sugar-sweetened beverage (SSB) has been linked to obesity in adults. While efforts were made to reduce SSB consumption, there were concerns that this may lead to compensatory increase in consumption of other caloric nutrients, such as alcohol. This study aimed to assess the association between consumption of SSB and consumption of alcoholic beverage, as well as the effect of substituting SSB with alcoholic beverage on waist circumference.

This a multicentre phase II clinical trial to establish if low dose continuous Panobinostat is effective and safe in patients with relapsed or refractory cancer. Who is it for? You may be eligible for this study if you are less than 40 years old and have relapsed or refractory osteosarcoma, rhabdoid tumour and/or neuroblastoma. Study details All participants will receive oral Panobinostat for up to 12 months after completing their conventional therapy. Participants will have physical examinations, blood tests, urine tests, ECGs and imaging, including MRI/CT, MIBG or FDG-PET (depending on tumour type). This study will test the effectiveness of this new drug in paediatric, adolescent and young adult patients in cases where treatment options are limited.

The aim of this study is to compare how effective different types of specialised mattresses are at healing pressure injuries. We are investigating if one type mattress helps these kinds of wounds heal faster than the other type of mattress. This study has been based on current practice within ACT Health Community Care services for management of this kind of injury. Participation in the study will include: - allocation of a pressure mattress, either an active or reactive mattress - provision of a pressure cushion for use when not resting in bed - standard wound care provided by the Community Care Nurses, including photographs of the wounds, which will be assessed for healing - occupational therapy assessment, including pressure injury prevention education - completion of two online surveys Participants were part of the study for up to 8 weeks. Data collection for this study has now been completed, with data being analysed and prepared for dissemination.

Delirium is a common medical condition characterised by sudden and fluctuating disturbances in thinking, attention and consciousness. Affecting up to one in four hospitalised older people, delirium is considered a medical emergency because it causes premature death, admission to nursing home, dementia, longer stays in hospital and loss of independence. Currently, there are no licenced treatments for people with delirium for use in the Emergency Department or on hospital wards. The most popular off-licence treatment for delirium, antipsychotics, was recently shown to worsen symptoms and increase death. The need to discover safe treatments is urgent. Recent research has identified significant changes in brain glucose (sugar) metabolism during an episode of delirium. Insulin receptors are widely expressed in the brain and insulin delivered via nasal spray (intranasal insulin) has been shown to increase glucose uptake in the brain. Intranasal insulin has been tested in older people and was found to be safe and may be associated with an improved cognitive function. The effect of intranasal insulin in delirium has previously not been evaluated. We will study intranasal insulin to treat delirium in people coming to the Emergency Department at Prince of Wales Hospital. We will conduct a randomised double blind placebo controlled trial of 100 patients and scientifically evaluate the effect of intranasal insulin compared to salt water (saline). Neither the Doctor nor the study participant knows which treatment the participant is receiving. Patients will be reviewed daily by an Aged Care Specialist while they have delirium and be followed up at six months. The primary objective is to evaluate if intranasal insulin reduces the duration of delirium in hospitalised older adults. Secondary objectives will assess if intranasal insulin decreases the length of hospital stay, reduces the percentage of people discharged to residential care, reduces death during admission and at six months, reduces delirium severity and preserves cognitive status six months post-delirium.

This is a prospective, observational cohort study assessing patient outcomes after joint replacement surgery. The purpose of this study is to assess clinical outcomes within the Investigator’s practice. The primary objective of this protocol is the implementation of an ongoing registry to collate and store patient outcomes collected routinely as part of the standard clinical pathway for hip and knee arthroplasty at the Investigator’s practice. Outcomes will include objective joint function, pain, satisfaction, quality of life, radiology and revision surgery. The secondary objective is to integrate the clinical outcomes with analyses provided by the Australian National Joint Replacement Registry. Recruitment will include all patients electing to undergo hip or knee arthroplasty surgery within the investigator's practice. Patients will undergo standard of care preoperative work-up, including the collection of demographic, medical history, radiology, pathology, and functional analysis. Patients will be required to complete the; EQ-5D 5L, and specific joint function outcomes will include Harris Hip Score (HHS), Oxford Hip Score (OHS), Oxford Knee Score (OKS), International Knee Society score (IKSS). Patient evaluation will be completed at the following time points: preoperatively and postoperatively at 2 to 6 weeks, 3 months, 12 months, 24 months and 5 years. The clinical outcomes of individual patients will be monitored up to 5 years postoperatively.

The aim of this study is to determine if pulmonary rehabilitation will effect cognitive function in people with COPD Participants will be invited to participate in the study when they perform the initial assessment for rehabilitation. All outcomes described will be collected (T1) They will then attend rehabilitation twice a week for 8 weeks and perform exercise training and self-management education. Exercise training involved 20 minutes of cycling and 20 minutes of walking plus upper and lower limb strength training. At completion of the rehabilitation program all outcomes will be reassessed (T3) and at six-months following the completion of pulmonary rehabilitation (T4)

Exercise has proven health benefits for older people regardless of age, ability or disease status. However, for many older people, there are substantial barriers to regular exercise participation. These include access to facilities and age-appropriate programs and restricted transport options that prevent older people from attending both social and physical activities.The aim of this study is to evaluate a model of care which has a preventative focus and will enable long-term exercise delivery and support within existing in-home care funding. The primary aim of this study is to improve the functional capacity of participants thereby increasing their ability to engage in activities of daily living.

Vancomycin is an intravenous antibiotic used in the treatment of serious infections, commonly seen in the Intensive and Critical Care Unit (ICCU). Unlike many antibiotics, vancomycin requires serum drug concentration monitoring to ensure both efficacy and safety. Traditionally vancomycin is dosed as an intravenous intermittent infusion every 8-12 hours. However, critically ill patients experience greater pharmacokinetic changes which can have a major impact on the dosage of vancomycin required to treat infection. There is emerging evidence to suggest that the administration of vancomycin by a continuous infusion may be more efficacious in achieving therapeutic serum concentrations, doing so promptly, and limiting nephrotoxicity which is a known adverse effect of the drug. The aims of this project are as follows 1. To evaluate the current practice administering vancomycin by intermittent infusion within the ICCU at Flinders Medical Centre (FMC)- phase one/Before 2. To develop and implement a protocol for the administration of vancomycin by continuous infusion- phase two/Implementation 3. By using a Before-and-After study design evaluate the efficacy of a protocol for the administration of vancomycin by continuous infusions, when compared to standard practice within the ICCU at FMC- phase three/After Data on the current practice of vancomycin dosing via intermittent infusion was commenced in February 2015, this data formed the basis for the Before group. The protocol was developed, using a dosing nomogram derived from a series of published studies identified from a literature review on the topic. This protocol underwent beta-testing and was implemented into the ICCU in March 2016 with concurrent education sessions. Prospective post-implementation data collection was undertaken, making up the After group.